Related Experiment Videos
Management of fever in neutropenic patients
1Division of Internal Medicine, Section of Infectious Diseases, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Abstract:
Substantial progress has been made in the management of febrile episodes in neutropenic patients, largely by the prompt administration of potent, broad-spectrum antimicrobial agents. During the past several decades, the spectrum of organisms has changed from a predominance of gram-negative pathogens to a predominance of gram-positive pathogens. In recent years, some hospitals have experienced an increase of infections caused by multi-drug-resistant pathogens. Hence, it is no longer possible to rely on standardized regimens, but antimicrobial therapy must be selected based on the predominant pathogens and antimicrobial susceptibility patterns at each institution. It is customary to initiate antifungal therapy empirically in those patients whose fever persists despite broad-spectrum antibacterial therapy. Alternatives now exist to amphotericin B, including lipid formulations of this drug, and fluconazole. It is critically important that each patient be carefully re-assessed before starting antifungal therapy, because there are many other potential causes for persistent fever, including resistant bacteria and viruses. Novel approaches to therapy include outpatient antibiotics, and use of growth factors as adjunctive therapy. There also has been a renewed interest in white blood cell transfusions. Although the prognosis for infection in neutropenic patients has improved greatly, new infectious problems have emerged that limit our successful management of these complications.
Insights
Management of febrile episodes in neutropenic patients has improved with prompt antimicrobial therapy. However, evolving pathogens and drug resistance necessitate individualized treatment strategies for better outcomes.
Area of Science:
- Infectious Diseases
- Hematology
- Oncology
Background:
- Febrile episodes in neutropenic patients have seen improved management through prompt broad-spectrum antimicrobial agents.
- The spectrum of causative organisms has shifted from gram-negative to gram-positive pathogens over decades.
- Emerging multi-drug-resistant pathogens present challenges to standardized treatment regimens.
Purpose of the Study:
- To review the current landscape of managing febrile episodes in neutropenic patients.
- To highlight the evolving challenges posed by changing pathogen prevalence and antimicrobial resistance.
- To discuss contemporary and novel therapeutic approaches.
Main Methods:
- Literature review of antimicrobial management strategies for neutropenic fever.
- Analysis of shifts in pathogen prevalence and antimicrobial susceptibility patterns.
- Evaluation of current and emerging therapeutic options, including antifungals and adjunctive therapies.
Main Results:
- Antimicrobial therapy must be tailored to institutional pathogen patterns due to increasing resistance.
- Empirical antifungal therapy is often initiated for persistent fever, with alternatives to amphotericin B available.
- Careful patient reassessment is crucial to identify non-bacterial causes of persistent fever.
Conclusions:
- Despite progress, managing infections in neutropenic patients remains complex due to emerging infectious problems.
- Individualized antimicrobial selection based on local susceptibility data is paramount.
- Novel strategies like outpatient antibiotics, growth factors, and white blood cell transfusions show promise.